干扰素驱动 HCV 表观基因组的瘢痕形成,并在病毒清除后产生可靶向的脆弱性。

Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance.

机构信息

Department of Molecular Pharmacology and Experimental TherapeuticsMayo ClinicRochesterMinnesotaUSA.

Department of PathologyYale School of MedicineNew HavenConnecticutUSA.

出版信息

Hepatology. 2022 Apr;75(4):983-996. doi: 10.1002/hep.32111. Epub 2021 Dec 15.

Abstract

BACKGROUND AND AIMS

Chronic HCV infection is a leading etiologic driver of cirrhosis and ultimately HCC. Of the approximately 71 million individuals chronically infected with HCV, 10%-20% are expected to develop severe liver complications in their lifetime. Epigenetic mechanisms including DNA methylation and histone modifications become profoundly disrupted in disease processes including liver disease.

APPROACH AND RESULTS

To understand how HCV infection influences the epigenome and whether these events remain as "scars" following cure of chronic HCV infection, we mapped genome-wide DNA methylation, four key regulatory histone modifications (H3K4me3, H3K4me1, H3K27ac, and H3K27me3), and open chromatin in parental and HCV-infected immortalized hepatocytes and the Huh7.5 HCC cell line, along with DNA methylation and gene-expression analyses following elimination of HCV in these models through treatment with interferon-α (IFN-α) or a direct-acting antiviral (DAA). Our data demonstrate that HCV infection profoundly affects the epigenome (particularly enhancers); HCV shares epigenetic targets with interferon-α targets; and an overwhelming majority of epigenetic changes induced by HCV remain as "scars" on the epigenome following viral cure. Similar findings are observed in primary human patient samples cured of chronic HCV infection. Supplementation of IFN-α/DAA antiviral regimens with DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine synergizes in reverting aberrant DNA methylation induced by HCV. Finally, both HCV-infected and cured cells displayed a blunted immune response, demonstrating a functional effect of epigenetic scarring.

CONCLUSIONS

Integration of epigenetic and transcriptional data elucidate key gene deregulation events driven by HCV infection and how this may underpin the long-term elevated risk for HCC in patients cured of HCV due to epigenome scarring.

摘要

背景和目的

慢性 HCV 感染是肝硬化和最终 HCC 的主要病因驱动因素。在大约 7100 万慢性 HCV 感染者中,预计有 10%-20%的人在其一生中会发展出严重的肝脏并发症。包括 DNA 甲基化和组蛋白修饰在内的表观遗传机制在包括肝脏疾病在内的疾病过程中会受到严重破坏。

方法和结果

为了了解 HCV 感染如何影响表观基因组,以及这些事件在慢性 HCV 感染治愈后是否仍然存在“疤痕”,我们绘制了全基因组 DNA 甲基化、四种关键调节组蛋白修饰(H3K4me3、H3K4me1、H3K27ac 和 H3K27me3)以及亲本和 HCV 感染的永生化肝细胞和 Huh7.5 HCC 细胞系中的开放染色质图谱,以及在这些模型中通过用干扰素-α(IFN-α)或直接作用抗病毒(DAA)治疗消除 HCV 后进行的 DNA 甲基化和基因表达分析。我们的数据表明,HCV 感染会深刻影响表观基因组(尤其是增强子);HCV 与干扰素-α的靶标共享表观遗传靶标;并且 HCV 诱导的绝大多数表观遗传变化在病毒治愈后仍然留在表观基因组上的“疤痕”中。在慢性 HCV 感染治愈的原发性人类患者样本中也观察到类似的发现。用 DNA 甲基转移酶抑制剂 5-氮杂-2'-脱氧胞苷补充 IFN-α/DAA 抗病毒方案可协同逆转 HCV 诱导的异常 DNA 甲基化。最后,感染 HCV 的细胞和治愈的细胞都表现出免疫反应迟钝,表明表观遗传“疤痕”具有功能效应。

结论

整合表观遗传学和转录组学数据阐明了 HCV 感染驱动的关键基因失调事件,以及这如何构成 HCV 治愈患者由于表观基因组“疤痕”而长期 HCC 风险增加的基础。

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索